Sat, Nov 22, 2014, 8:30 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

RPX Corporation (RPXC) Message Board

swing_trader37 8 posts  |  Last Activity: Oct 5, 2014 3:49 PM Member since: Jun 9, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • swing_trader37 by swing_trader37 Oct 5, 2014 3:49 PM Flag

    In regards to MYDICAR, historically, these gene transfer techniques have not worked. Approximately 60 percent of all patients in the United States currently have AAV1 neutralizing antibodies to the SERCA2a enzyme. Also, they are only targeting systolic heart failure initially. The main potential in my opinion might be with the stem cell therapy. Celladon's stem cell therapy is only in the pre-clinical phase. I believe NeoStem has a better stem cell therapy. The company is developing AMR-001, an autologous adult stem cell product to treat damaged heart muscle following an acute myocardial infarction. It is currently in phase 2 of its PreSERVE clinical trial.

  • swing_trader37 swing_trader37 Oct 2, 2014 8:33 PM Flag

    Because there are a lot of incredibly stupid people in this world that enjoy losing money.

  • swing_trader37 swing_trader37 Sep 22, 2014 8:39 PM Flag

    Because MSLP has a much smaller float of 7.7 million shares vs. 45 million for MRIC. It's much easier to move MSLP with such a small and demand. With a float of 45 million MRIC needs institutional investors to move the stock which won't happen until it trades on a national exchange. Not to mention MSLP has a much better PR firm and is much better about attending investor conferences and spreading the work about their company and products...something MRIC really needs to work on.

  • By Dwight Einhorn
    September 2, 2014 8:47 AM

    In a report published Tuesday, MLV & Co. analyst George B. Zavoico reiterated a Hold rating and $5.00 price target on Cytokinetics (NASDAQ: CYTK).

    In the report, MLV & Co noted, “Over the weekend, results of the international, randomized, double-blind Phase III PARADIGM-HF trial of LCZ696 versus enalapril in patients with chronic heart failure (CHF) were presented at the European Society of Cardiology (ESC) annual meeting in Barcelona, Spain. The trial was stopped early following an interim analysis by an independent Data and Safety and Monitoring Committee (DSMC) in March 2014 showing that LCZ696 demonstrated a statistically significant clinical benefit versus enalapril after a median follow-up of 27 months. If LCZ696 becomes the standard of care for patients with CHF, as some cardiologists now expect (based on comments at the ESC meeting), then we think it is likely that a combination of Cytokinetics' omecamtiv mecarbil with LCZ696 will have to be evaluated. Due to the different mechanisms of action we think omecamtiv may have an additive or synergistic effect with LCZ696, without sacrificing safety. We maintain our HOLD recommendation and $5.00 price target based on uncertainties regarding future development of tirasemtiv for the treatment of amyotrophic lateral sclerosis (ALS). We note that the PARADIGM-HF results do not change our positive outlook for omecamtiv.”

    Cytokinetics closed on Friday at $4.28.

  • swing_trader37 by swing_trader37 Sep 19, 2014 10:57 AM Flag

    Not only is there LCZ696 by Novartis to contend with, but now there is also Omecamtiv Mecarbil by Cytokinetics (CYTK). Omecamtiv Mecarbil is a novel, small-molecule, direct activator of cardiac myosin, the motor protein that causes cardiac contraction. It is being evaluated as a potential treatment of heart failure in both intravenous and oral formulations with application across the continuum of care for heart failure patients from in-hospital to outpatient settings. Omecamtiv Mecarbil is now in a broad clinical trials program designed to evaluate this novel drug candidate in a variety of patients with heart failure.

    Cytokinetics has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure.

  • The minimum price to be listed on the Nasdaq is $4. As long as MRIC trades on the OTC market, it will never go anywhere. It needs to trade on a national exchange like the Nasdaq so that it can get analyst coverage and allow institutions to buy. Institutions cannot buy OTC stocks and analysts won't cover them. The company also needs to hire a PR firm and do a better job of attending investor conferences to spread the word about their device. Until the company takes these actions the stock will continue to languish in the $1 range IMO.

  • I do NOT think HTWR, THOR or SSH will be impacted at all by drugs such as MYDICAR or LCZ696. If anything, drugs will be used in conjunction with devices. But the devices will do most of the work and provide most of the efficacy. I do however think that LCZ696 will make MYDICAR obsolete and I would not want to be long CLDN stock right now.

  • swing_trader37 by swing_trader37 Sep 2, 2014 10:55 PM Flag

    I would not want to be long CLDN after today's news on LCZ696. However, I do NOT think LCZ696 will have any impact on HF device makers THOR, HTWR, and SSH. Devices will always be superior to drugs for the treatment of HF.

13.25-0.06(-0.45%)Nov 21 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exa Corporation
NasdaqGMFri, Nov 21, 2014 3:59 PM EST
Celgene Corporation
NasdaqGSFri, Nov 21, 2014 4:00 PM EST